Lipitor Related Published Studies
Well-designed clinical trials related to Lipitor (Atorvastatin)
Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in
atorvastatin trials. [2015]
Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib
administered as monotherapy or in combination with atorvastatin in Japanese
patients with dyslipidemia. [2014]
Efficacy of topical atorvastatin for the treatment of pressure ulcers: a
randomized clinical trial. [2014]
Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in
type 2 diabetes mellitus patients: a randomized pilot study. [2014]
Patients with stable coronary artery disease receiving chronic statin treatment
who are undergoing noncardiac emergency surgery benefit from acute atorvastatin
reload. [2014]
Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled
trial. [2014]
A Multicentre Randomised Trial of Atorvastatin Therapy in Intensive Care Patients
with Severe Sepsis. [2013]
Pitavastatin and Atorvastatin double-blind randomized comPArative study among
hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan
(PAPAGO-T Study). [2013]
Effects of low-dose atorvastatin on arterial stiffness and central aortic
pressure augmentation in patients with hypertension and hypercholesterolemia. [2013]
Atorvastatin with or without an antibody to PCSK9 in primary
hypercholesterolemia. [2012]
Atorvastatin treatment improves diabetic polyneuropathy electrophysiological
changes in non-insulin dependent diabetic patients: a double blind, randomized
clinical trial. [2012]
STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized
placebo-controlled trial evaluating perioperative atorvastatin therapy in
noncardiac surgery. [2012]
The differential effect of statins on oxidative stress and endothelial function:
atorvastatin versus pravastatin. [2012]
Use of atorvastatin in systemic lupus erythematosus in children and adolescents. [2012]
A pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery. [2011.11.24]
Effects of Preoperative Short Term Use of Atorvastatin on Endothelial Progenitor Cells after Coronary Surgery: A Randomized, Controlled Trial. [2011.11.11]
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. [2011.11.02]
Use of atorvastatin in systemic lupus erythematosus in children and adolescents. [2011.10.26]
Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk. [2011.10.10]
Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: A double-blind, placebo-controlled, randomized trial. [2011.09.13]
Oral atorvastatin therapy increases nitric oxide-dependent cutaneous vasodilation in humans by decreasing ascorbate-sensitive oxidants. [2011.09]
Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk. [2011.08]
Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial. [2011.07.01]
The atorvastatin during ischemic stroke study: a pilot randomized controlled trial. [2011.07]
Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. [2011.07]
Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent. [2011.06.01]
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). [2011.06]
The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. [2011.06]
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. [2011.06]
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). [2011.06]
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. [2011.05.25]
Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. [2011.05.04]
Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stable angina pectoris undergoing elective percutaneous coronary intervention. [2011.05.01]
High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. [2011.05]
Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. [2011.05]
Effect of oral atorvastatin on CD4+CD25+ regulatory T cells, FoxP3 expression, and prognosis in patients with ST-segment elevated myocardial infarction before primary percutaneous coronary intervention. [2011.05]
Effects of short-term treatment with atorvastatin in smokers with asthma--a randomized controlled trial. [2011.04.07]
Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. [2011.04.05]
Benefit and tolerability of the coadministration of ezetimibe and atorvastatin in acute coronary syndrome patients. [2011.04]
An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. [2011.04]
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. [2011.03.15]
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. [2011.03.11]
Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). [2011.03]
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. [2011.02.01]
Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries. [2011.01.25]
High-dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine. [2011.01.01]
Role of preoperative atorvastatin administration in protection against postoperative atrial fibrillation following conventional coronary artery bypass grafting. [2011]
Effects of prescription omega-3-acid ethyl esters, coadministered with
atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein
CIII, and lipoprotein-associated phospholipase A2 mass in men and women with
mixed dyslipidemia. [2011]
Atorvastatin for the treatment of plaque-type psoriasis. [2011]
Influence of atorvastatin on coronary calcifications and myocardial perfusion
defects in systemic lupus erythematosus patients: a prospective, randomized,
double-masked, placebo-controlled study. [2011]
High dose atorvastatin decreases cellular markers of immune activation without
affecting HIV-1 RNA levels: results of a double-blind randomized placebo
controlled clinical trial. [2011]
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver
disease: the St Francis Heart Study randomized clinical trial. [2011]
Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention. [2010.12]
Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography. [2010.10]
Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. [2010.09.14]
On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). [2010.08.15]
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). [2010.08.01]
Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. [2010.07.15]
Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. [2010.07.10]
Short-term therapy with high dose atorvastatin in patients with coronary artery disease can reduce inflammatory process. [2010.07]
Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy. [2010.06]
Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease. [2010.06]
Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. [2010.06]
Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome Trial (the JAPAN-ACS Trial). [2010.05.25]
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial. [2010.05.06]
Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study. [2010.05]
Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes. [2010.05]
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. [2010.05]
Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease. [2010.04]
Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. [2010.04]
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. [2010.04]
Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. [2010.03.23]
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. [2010.03.23]
Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). [2010.03.01]
Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study. [2010.03]
Effect of atorvastatin on cellular adhesion molecules on leukocytes in patients with normocholesterolemic coronary artery disease. [2010.03]
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. [2010.03]
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia. [2010.03]
Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. [2010.03]
Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study. [2010.03]
Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. [2010.02.01]
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). [2010.02.01]
Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (CanACTFAST) study. [2010.02]
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. [2010.02]
[Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension] [2010]
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. [2010]
Short-term therapy with high dose atorvastatin in patients with coronary artery
disease can reduce inflammatory process. [2010]
Attainment of Canadian and European guidelines' lipid targets with atorvastatin
plus ezetimibe vs. doubling the dose of atorvastatin. [2010]
[A comparative study of the efficacy and safety Zhibitai and atorvastatin]. [Article in Chinese] [2010]
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and
rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of
achievement of Joint British Societies (JBS-2) cholesterol targets. [2010]
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV
risk burden using amlodipine/atorvastatin single-pill therapy in treated
hypertensive participants in a randomized controlled trial. [2010]
Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study. [2010]
Atorvastatin causes insulin resistance and increases ambient glycemia in
hypercholesterolemic patients. [2010]
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. [2009.12]
[Effect of atorvastatin on postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting] [2009.11.17]
Effect of Preoperative Atorvastatin Therapy on Atrial Fibrillation Following Off-Pump Coronary Artery Bypass Grafting. [2009.10.13]
Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. [2009.10.09]
[Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome] [2009.10]
Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. [2009.09.01]
Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. [2009.09]
Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. [2009.08.21]
|